Pleuropulmonary and Lymph Node Progression after Docetaxel - Benefits from Treatment with Cabazitaxel in Metastatic Prostate Cancer
Introduction: To date, there are no guidelines for a rational and more favourable sequence of treatment after docetaxel. Two drugs (cabazitaxel and abiraterone) have recently been approved as second-line treatment after docetaxel failure in metastatic castration-resistant prostate cancer (mCRPC), bu...
| मुख्य लेखकों: | , , , , |
|---|---|
| स्वरूप: | लेख |
| भाषा: | English |
| प्रकाशित: |
Karger Publishers
2013-07-01
|
| श्रृंखला: | Case Reports in Oncology |
| विषय: | |
| ऑनलाइन पहुंच: | http://www.karger.com/Article/FullText/354089 |